{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:36:16Z","timestamp":1791300976933,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T00:00:00Z","timestamp":1419552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>ABO\u2010incompatible organ transplantation requires pre\u2010transplant conditioning to reduce ABO antibody levels in the recipients. With respect to replacement fluids used in plasma exchange, we intended to verify whether fresh\u2010frozen plasma (FFP) containing soluble ABO substance (SAS) is more effective than albumin solution in reducing ABO IgG antibody levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Apheresis data were retrospectively studied for in vivo effects, and in vitro plasma mixing studies were prospectively performed. The amount of ABO IgG antibodies bound to red cells was measured as the mean fluorescence intensity (MFI) using flow cytometry. Neutralization of ABO antibodies in the recipientst plasma by an ABO\u2010incompatible donornc plasma was measured using the inhibition assay principle. The MFI value of the unneutralized control tube was divided by that of the neutralized test tube (neutralizing\u2010capacity index, NCI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The plasma exchange procedures replaced with group AB FFP showed a significantly greater decreased titer than those replaced with albumin (<jats:italic>P<\/jats:italic>\u2009=\u20090.010). The in vitro plasma mixing study simulating plasma exchange also produced consistent results. When the pooled group O plasma was neutralized for anti\u2010A by individual group AB plasmas (AB\u2010to\u2010O, <jats:italic>N<\/jats:italic>\u2009=\u200930), the NCI was 12.8\u2009\u00b1\u20095.4 (6.5\u201329.5). When this group O plasma was neutralized by pooled group AB or A plasma, the repeatedly measured NCI (<jats:italic>N<\/jats:italic>\u2009=\u20095) of A\u2010to\u2010O (11.4\u2009\u00b1\u20091.4) was not significantly different from that of AB\u2010to\u2010O (9.7\u2009\u00b1\u20091.3, <jats:italic>P<\/jats:italic>\u2009=\u20090.074).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ABO antibody levels are reduced more effectively by group AB FFP than by albumin. Either group AB or donor type (group A or B) FFP can be infused to group O recipients. FFP units with higher SAS levels can be selected from multiple available candidate units using our protocol for measuring the neutralizing\u2010capacity. J. Clin. Apheresis 30:288\u2013296, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jca.21378","type":"journal-article","created":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T15:10:21Z","timestamp":1419606621000},"page":"288-296","source":"Crossref","is-referenced-by-count":11,"title":["Benefits of fresh\u2010frozen plasma as a replacement fluid to neutralize <scp>ABO<\/scp> antibodies"],"prefix":"10.1002","volume":"30","author":[{"given":"Dong Il","family":"Won","sequence":"first","affiliation":[{"name":"Department of Clinical Pathology Kyungpook National University School of Medicine Daegu Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Ham","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology Kyungpook National University School of Medicine Daegu Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Duck","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kyungpook National University School of Medicine Daegu Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Soo","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology Kyungpook National University School of Medicine Daegu Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Chang","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Maryknoll Medical Center Busan Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,26]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12249"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318245b2af"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)01947-9"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200210270-00023"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200207150-00014"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199509000-00004"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2003.50011"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199407000-00009"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199310000-00001"},{"key":"e_1_2_5_11_1","first-page":"291\u2013","volume-title":"Technical Manual","author":"Cooling L.","year":"2014"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2004.05.007"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355855"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1309\/LM1O8F7MLLYIPIMZ"},{"key":"e_1_2_5_15_1","first-page":"645\u2013","volume-title":"Technical Manual","author":"Davenport RD.","year":"2014"},{"key":"e_1_2_5_16_1","article-title":"Differential modulation of donor\u2010specific antibodies after B\u2010cell depleting therapies to cure chronic antibody mediated rejection","author":"Touzot M","journal-title":"Transplantation"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-082719"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21378","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:55:33Z","timestamp":1696362933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,26]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1002\/jca.21378"],"URL":"https:\/\/doi.org\/10.1002\/jca.21378","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,26]]}}}